Both medications should be used with caution in patients with a history of pancreatitis. They are not recommended for individuals with a personal or family history of medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Long-term effects of the medications are still being studied.
It's important to note that both medications should be used as part of a comprehensive treatment plan that includes diet, exercise, and regular blood sugar monitoring, and should only be used under the guidance and supervision of a healthcare professional. For the most accurate and personalized information, it's best to consult a healthcare provider.

As with Semaglutide, maintaining weight loss achieved with Tirzepatide will likely require ongoing lifestyle adjustments in diet and physical activity. Long-term studies are needed to fully understand the sustainability of weight loss with Tirzepatide.

It's important to remember that while these medications can aid in weight loss, they should be part of a broader lifestyle change, including diet and exercise, for best results. Consultation with healthcare professionals is crucial to determine the best treatment plan based on individual health needs and conditions.

Semaglutide is a medication used for the treatment of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists. It helps control blood sugar levels by increasing insulin secretion and decreasing glucagon secretion when blood sugar levels are high.

Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain. Like Semaglutide, most side effects are mild to moderate in severity and tend to diminish over time.

Common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. Most side effects are mild and tend to diminish over time.

Yes, appointments are highly encouraged to guarantee service when you need it most. We can book your appointment as little as an hour before treatment but concierge should be scheduled out 24-48 hours in advance for guaranteed appointments.

In clinical trials, participants using Semaglutide experienced significant weight loss. On average, people lost about 10-15% of their body weight over 68 weeks when using the medication alongside diet and exercise.

Semaglutide works by mimicking a hormone that targets areas of the brain involved in appetite regulation, leading to reduced hunger and calorie intake.

Tirzepatide has shown significant weight loss effects in clinical trials, with some studies reporting an average weight loss of around 15-20% of body weight over a period of 72 weeks, making it a promising agent for weight management.

Tirzepatide combines the actions of GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonists, contributing to reduced hunger, increased feelings of fullness, and improved control of blood sugar levels, which collectively support weight loss.

Semaglutide and Tirzepatide is administered as a once-weekly subcutaneous injection. It's available under brand names such as Ozempic for diabetes and Wegovy for weight management.